Joint commitment for the availability of vaccines
The third revision of the concept on delivery shortages of vaccines for human use against infectious diseases has been completed successfully. The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, has improved the procedure for reports on supply shortages for manufacturers of vaccines.
Issue 2/2018 of the Pharmacovigilance Bulletin is online
The current Pharmacovigilance Bulletin presents new measures intended to prevent exposure to Valproat during pregnancy, suspected cases of adverse drug reactions under Zinbryta (Daclizumab) treatment and the safety profile evaluation of a meningococcal B vaccine based on pharmacovigilance data after marketing authorisation. Other topics include an online survey on the safety of blood donors and pharmacovigilance in child and youth psychiatry.
Towards universal influenza vaccines – is Neuraminidase underrated?
While up to now, the constantly changing hemagglutinin has been considered the main protective antigen in influenza vaccines, the more strongly conserved neuraminidase has now aroused the interest of scientists. Researchers at the PEI have shown that the potential of the neuraminidase to confer a broader protection against influenza strains of the same subtype is higher than previously thought.